In the United States, the Centers for Disease Control (CDC), estimates 37 million people have chronic kidney disease (CKD), and even more staggering, 90 percent of them are unaware of it. 1 in 3 American adults are at risk for CKD, with a disproportionate number of those self-identifying as Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, and Native Hawaiian or Other Pacific Islander. The healthcare costs for treating CKD are enormous. In 2019, treating Medicare beneficiaries with CKD cost $87.2 billion and treating people with end-stage renal disease (ESRD) cost an additional $37.3 billion.

Some people are more likely than others to develop kidney disease; however, diabetes and high blood pressure, or hypertension, are responsible for approximately two-thirds of chronic kidney disease cases. In order to improve CKD testing in people with diabetes, the National Kidney Foundation (NKF) developed new measures to improve rates of comprehensive kidney health evaluation in patients with diabetes to more consistently identify and treat CKD in this high-risk population. Specifically, to address potential gaps in care, the NKF developed HEDIS® (Healthcare Effectiveness Data and Information Set) and MIPS (Merit-based Incentive Payment System) measures for Kidney Health Evaluation for Adults with Diabetes. The HEDIS measure was released in 2020 and is part of HEDIS Measurement Year 2022.

For health plans, it is imperative that they consider implementing modern solutions for screening members that are safe, scalable, and convenient, to provide the preventative care their members’ needs. BioIQ helps streamline the process of fulfilling HEDIS mandates and increasing Star Ratings by providing members with the preventive and chronic care that they need to stay healthy.

BioIQ provides a modern approach to member wellness with a wide selection of test kits to identify and test at-risk populations for prediabetes, diabetes, chronic kidney disease, cardiovascular disease, and hepatitis C from the convenience and comfort of home. Our Kidney Test uses one finger stick of blood to test for 2 common measures of kidney function: serum creatinine and calculated eGFR.

  • Serum Creatinine: A measure of creatinine and eGFR is a calculation that determines how well the blood is filtered by the kidneys, which is one way to measure remaining kidney function.
  • eGFR: eGFR can also be used to find the stage of chronic kidney disease.

BioIQ enables health plans to close care gaps, increase member engagement and improve quality ratings. With BioIQ, health plans have a simple way to configure screening programs for target segments of their member populations.

Our solutions enable health plans, enterprise companies, and government agencies to positively impact cost and outcomes through early identification and intervention of CKD and other chronic diseases for their member groups. To learn more, contact us today!

Share This